Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Serum Scores A Double - HPV Vaccine In India, Novavax Vaccine In US

Demand High For HPV, Low For COVID-19 Vaccine

Executive Summary

Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.

You may also be interested in...



GSK Eases Cervarix Out Of India, Eyes On Trajectory Of Synflorix

GSK discontinues Cervarix in India as part of portfolio rationalization efforts against the backdrop of the arrival of Serum’s 'affordable' quadrivalent HPV vaccine. The heat is also believed to be on the UK drugmaker’s pneumococcal vaccine Synflorix in the country.

Bharat Biotech Debuts World’s First Exclusively Intranasal COVID-19 Vaccine

With the world’s first exclusively intranasal COVID-19 vaccine against COVID-19 getting restricted use approval in India, Bharat Biotech/Washington University St. Louis offer an easy-to-use immunization option. But is it too little too late?

Monkeypox Vaccines – Golden Opportunity Or False Dawn?

While Moderna plans preclinical studies and Tonix Pharma’s candidate is to enter trials in H1, Bavarian Nordic is seeking US and Indian manufacturing partners for its approved monkeypox vaccine. Scrip examines if the disease presents an opportunity for vaccine makers, like COVID-19 did or it could go the H1N1 way

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146741

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel